Transporter, Symporter, System N amino acid transporter, Member of solute carrier family 38 (SLC38)
01
Overview
Sodium-coupled neutral amino acid transporter 3 (SLC38A3/SNAT3) is a plasma membrane transporter responsible for the electroneutral cotransport of neutral amino acids (primarily glutamine, histidine, and asparagine) together with sodium ions, coupled to proton antiport. It is highly expressed in the brain (astrocytes and blood-brain barrier), liver, kidney, heart, and skeletal muscle. In the CNS, it enables the glutamate–GABA–glutamine cycle essential for neurotransmitter recycling. In the kidney and liver, it facilitates ammonia detoxification and supports acid-base balance via renal ammoniagenesis. SLC38A3 is also implicated in glucose metabolism, nitrogen balance, and may play pathophysiological roles in conditions such as epilepsy, glioma, and metabolic acidosis. Dysfunction or altered expression of SLC38A3 has direct disease relevance in neurodevelopmental and metabolic disorders[1][2][4][6].
Other names
SLC38A3SNAT3SN1NAT1G17N-system amino acid transporter 1Na(+)-coupled neutral amino acid transporter 3Solute carrier family 38 member 3System N amino acid transporter 1Sodium-coupled neutral amino acid transporter 3
02
Mechanism of action
Amino acid transport modulation via sodium-coupled symport and H+ antiport activity. Drug mechanisms, if developed, would likely inhibit or modulate glutamine transport to affect neurotransmitter cycling, nitrogen metabolism, or cell proliferation.
03
Biological functions
Amino acid transport (specifically glutamine, asparagine, and histidine)Glutamate-GABA-glutamine cycle in brain (shuttling glutamine for neurotransmitter replenishment)Energy metabolism (substrate supply for gluconeogenesis and insulin regulation)Ammonia detoxification (hepatic and renal ammoniagenesis)Acid-base balance (renal response during metabolic acidosis)Glucose metabolismGestation (role in placenta)
04
Disease associations
Developmental and epileptic encephalopathy 102Non-specific early-onset epileptic encephalopathyCancer (e.g., glioma) (upregulation in gliomas)Chronic kidney disease (potential protection of podocytes)Metabolic acidosis-related kidney dysfunctionOther (possibly involved in glucose and nitrogen metabolism disorders)
05
Safety considerations
Disruption of glutamine, histidine, and asparagine homeostasis may impact neuronal function, hepatic ammonia detoxification, and renal acid-base balance—potential for CNS, metabolic, and renal side effects if targeted therapeuticallyPossibility of metabolic acidosis or neurological issues if transporter function is impairedBroad tissue expression suggests risk for off-target metabolic effects
06
Interacting drugs
No well-established direct pharmacological inhibitors or in-market drugs targeting SLC38A3 are documented as of the current evidence; research compounds and inhibitors may exist for research use, but no clinical agents are definitively described.
07
Biomarkers
Increased SNAT3 expression in advanced gliomas may serve as a biomarker for brain tumor diagnosis or progressionPotential marker in epileptic encephalopathies associated with SLC38A3 mutationsPossible renal biomarker for acidosis-induced ammoniagenesisNone mainstream for clinical patient selection
Beyond the preview
Go deeper on Sodium-coupled neutral amino acid transporter 3 (SLC38A3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Full profile access
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Full profile access
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Full profile access
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Full profile access
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Full profile access
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Full profile access
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sodium-coupled neutral amino acid transporter 3 (SLC38A3).